AIM ImmunoTech (AIM) Operating Income (2010 - 2026)
AIM ImmunoTech's (AIM) quarterly Operating Income came in at -$2.2 million in Q1 2026, up 38.49% YoY from -$1.6 million in Q1 2025, and up 24.59% on a QoQ basis from -$3.0 million in Q4 2025.
AIM ImmunoTech (AIM) Operating Income (2010 - 2026) Analysis & Trends
AIM ImmunoTech (AIM) has 17 years of Operating Income data on file, last reported at -$2.2 million in Q1 2026.
- Quarterly Operating Income rose 38.49% year-over-year to -$2.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$10.3 million (up 41.83% YoY) and the FY2025 annual result came in at -$11.7 million, up 41.01% from the prior year.
- Operating Income improved to -$2.2 million in Q1 2026, from -$3.0 million in the prior quarter.
- In the past five years, Operating Income ranged from a high of -$2.2 million in Q1 2026 to a low of -$14.0 million in Q4 2023.
- A 5-year average of -$5.0 million and a median of -$4.5 million in 2024 frame the typical range for Operating Income.
- Annual changes were most pronounced in 2023 — Operating Income tumbled 152.05% — and 2024, when it jumped 58.19%.
- Tracing AIM's Operating Income over 5 years: stood at -$5.6 million in 2022, then plunged by 152.05% to -$14.0 million in 2023, then soared by 58.19% to -$5.9 million in 2024, then surged by 49.58% to -$3.0 million in 2025, then advanced by 24.59% to -$2.2 million in 2026.
- The last three Operating Income figures came in at -$2.2 million (Q1 2026), -$3.0 million (Q4 2025), and -$2.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.66 Bn | 131.81 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.52 Bn | 78.52 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 65.30 Bn | 60.11 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 59.18 Bn | 54.04 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 42.08 Bn | 36.98 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.77 Bn | 28.46 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 28.13 Bn | 9.74 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.51 Bn | 26.35 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 27.16 Bn | 26.32 Bn | - | 133.12 Mn |
| 10 | AIM ImmunoTech | 4.45 Mn | -5.51 Mn | 21,000.00 | -3.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.51 Mn |
| Mar 31, 2026 | -2.23 Mn |
| Dec 31, 2025 | -2.95 Mn |
| Sep 30, 2025 | -2.45 Mn |
| Jun 30, 2025 | -2.65 Mn |
| Mar 31, 2025 | -3.62 Mn |
| Dec 31, 2024 | -5.86 Mn |
| Sep 30, 2024 | -4.49 Mn |
| Jun 30, 2024 | -3.69 Mn |
| Mar 31, 2024 | -5.73 Mn |
| Dec 31, 2023 | -14.00 Mn |
| Sep 30, 2023 | -8.16 Mn |
| Jun 30, 2023 | -5.46 Mn |
| Mar 31, 2023 | -4.30 Mn |
| Dec 31, 2022 | -5.56 Mn |
| Sep 30, 2022 | -6.52 Mn |
| Jun 30, 2022 | -4.70 Mn |
| Mar 31, 2022 | -3.15 Mn |
| Dec 31, 2021 | -7.45 Mn |
| Sep 30, 2021 | -3.93 Mn |